KMDA Kamada Ltd
XNAS
8.08
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KMDA
$8.08
—
Key stats
$8.08
- 52-Week Range
- $6.55 – $9.35
- YTD
- +14.94%
- IV Rank (30D)
- 7.44
- Straddle Price
- $1.55
- P/C Vol Ratio
- 4.47
- Market Cap
- $0.4B
- Open
- $7.90
- Day Range
- $7.90 – $8.11
- Volume
- 72,768
- Prev Close
- $7.78
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.27% |
| Beta vs SPY | 0.83 |
| Cost of Equity (CAPM) | 9.41% (VRP-adj) |
| WACC | 9.38% |
| Volatility Risk Premium | +73.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -10.8% |
| Book / Price | 91.9% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $8.05 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $8.40 |
| Bollinger Width / SMA20 | 200.2% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, GILD, ILMN, MRNA, REGN, RVMD, VRTX
Blended Fair Value
$92.37
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | $6.75 | 0% | |
| Peer P/E | n/a | 0% | median 29.1× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 20.7× · 6 peers |
| Peer P/B | $92.37 | 100% | median 12.9× · 8 peers |
| Peer P/S | n/a | 0% | median 6.0× · 7 peers |
| Market Anchor (SMA50) | $8.05 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.4B
- Employees
- 462
- List Date
- 2013-05-31
- CIK
- 0001567529
- Next Earnings
- 2026-11-09
- EPS Forecast
- $0.13 (3 est.)
- Homepage
- https://www.kamada.com
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -0.15% | -8.33% | 12.77% | -6.98% | 6.32% | 18.35% | 3.66% |
| Feb | -9.84% | -8.57% | -7.20% | 8.62% | 1.92% | 5.58% | -1.58% |
| Mar | -0.16% | -4.00% | 5.57% | -11.93% | -2.65% | -8.05% | -3.54% |
| Apr | -2.58% | -3.07% | -0.85% | -6.95% | -3.43% | -3.90% | -3.46% |
| May | -2.49% | -12.26% | 4.77% | -1.86% | 4.26% | -4.87% | -2.08% |
| Jun | 0.17% | -2.59% | 11.76% | -7.46% | 12.32% | -4.68% | 1.59% |
| Jul | -7.33% | 15.28% | -4.64% | 16.98% | -4.77% | -5.93% | 1.60% |
| Aug | -2.89% | -1.19% | 14.31% | 3.79% | -4.16% | 13.83% | 3.95% |
| Sep | -2.57% | -8.15% | -7.29% | -1.47% | -1.14% | 0.95% | -3.28% |
| Oct | 7.53% | 0.67% | -21.44% | 9.54% | 1.17% | -1.46%* | -0.67% |
| Nov | 5.77% | 2.17% | 6.05% | -0.51% | -2.76% | -- | 2.14% |
| Dec | 5.11% | -14.68% | 31.61% | 1.67% | 4.90% | -- | 5.72% |
| Total | -10.35% | -38.80% | 42.13% | -0.32% | 11.08% | 6.65% | 1.73% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $8.41
SMA 50: $8.07
SMA 200: $8.00
Current: $8.08
EMA 12: $8.20
EMA 26: $8.24
MACD: -0.0479 | Signal: -0.1054
BULLISH
ADX (14): 20.87
WEAK TREND
+DI: 24.62
−DI: 27.27
Momentum Oscillators
RSI (14): 46.48
NEUTRAL
Stoch %K: 14.11
Stoch %D: 12.02
Williams %R: -68.11
Volume & Volatility
BB Upper: $9.10
BB Lower: $7.72
NEUTRAL
OBV: 4,288,537
Vol SMA 20: 117,888
Vol ROC: -20.95%
ATR: $0.27
True Range: $0.33
HV 20: 42.7%
HV 30: 38.7%
HV 60: 36.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-11T00:00:00 – 2026-10-09T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: KMDA
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Positive news sentiment surrounding FDA approvals
- Momentum signals indicating overbought conditions
- Strong institutional interest and volume trends
Primary Risks:
- Overbought conditions may lead to short-term pullback
- High volatility levels increase risk of sharp price movements
Investment Thesis: KMDA presents a compelling bullish case, driven by positive news sentiment and momentum indicators. The stock's high volatility and beta levels highlight the potential for significant price moves. However, caution is advised due to overbought conditions, which may lead to short-term retracement.
Recent News Sentiment Impact: Positive news headlines (FDA approvals) have contributed to the bullish trend, with a sentiment score of 0.8/1.0.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Bullish
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- Upper Bollinger Band: $8.12
- Middle Line: $7.36
- Lower Bollinger Band: $6.60
Momentum Signals:
- RSI (14): 72.35 (overbought)
- MACD: 0.21 / Signal: 0.12 / Histogram: 0.09 (bullish)
Volume Analysis:
- Volume SMA 20: 135815.78
- On-Balance Volume (OBV): 4271968.72
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines surrounding FDA approvals have driven the stock's price movement.
Sentiment Assessment: Aggregate sentiment score: 0.8/1.0 (positive)
Catalyst Identification: Upcoming earnings release on May 13, 2026
Market Narrative: News sentiment aligns with technical signals, reinforcing the bullish trend.
Risk & Volatility Assessment
Beta Interpretation: Beta level of 1.06 indicates a high-risk stock relative to the market.
Volatility Regime: Current volatility levels are above average, suggesting a higher risk environment.
Options Market Signals:
- IV Rank: 20.4% (Low)
- Put/Call Volume Ratio: 0.33 (Bullish sentiment)
Downside Protection: Support levels at $7.36 and $6.60 provide potential downside protection.
Market Context & Positioning
Sector Performance: KMDA's sector is performing above average, providing a positive market context.
Institutional Activity: Strong institutional interest and volume trends suggest continued support for the stock.
Correlation Analysis: R-squared interpretation: 0.41 (above average correlation with the market)
Relative Valuation: Position within trading range: Bullish
Key Levels & Action Items
Critical Price Levels:
- Support at $7.36
- Resistance at $8.12
Breakout/Breakdown Levels: No clear breakout/breakdown levels identified.
Time-Sensitive Catalysts: Upcoming earnings release on May 13, 2026
Risk Management: Stop-loss levels and position sizing considerations should be implemented to manage risk.
Please note that this report is based on the provided data and is intended to provide a comprehensive analysis of KMDA's stock performance.
Generated
News
All KMDA news →
KMDA Options Activity & IV Rank
KMDA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 78.4%
7-DTE IV: —
Expected Move: $1.55
7-DTE Move: $2.83
Days to Exp: 42 (2026-11-20)
Options Flow
Call Volume: 34
Put Volume: 152
P/C Volume: 4.471
BEARISH
Call OI: 71
Put OI: 10
P/C OI: 0.141
Total OI: 81
ATM Options Pricing
ATM Call: $1.05
ATM Put: $0.50
Call %: 13.0%
Put %: 6.2%
Chain Summary
Chain Volume: 282
Chain OI: 314
Last Updated: 10/9/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 88th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
88%
vs own history
GEX tilt
+1.00
OI-weighted, today
Vanna tilt
+0.39
δ-sensitivity to IV
Charm tilt
-0.19
δ-decay vs time
Vanna tilt +0.39: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 9 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 9 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)7.4LowOct 9
Straddle Price (30 DTE)$1.55Oct 9
Beta Analysis
Risk Metrics
Beta: 1.0371
Alpha: 5.28%
Correlation: 0.3823
R-Squared: 14.6%
Stock Volatility: 35.4%
Market Volatility: 13.0%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own KMDA
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $5.4M | #1412 of 3138 | -2.7% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $214K | #3462 of 3717 | -37.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $106K | #5781 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KMDA Institutional Ownership (13F)
Latest filings — 2026-06-30
? 13F Guide
Diluted shares outstanding: 37,651,661 (as of 2016-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
KMDA Insider Trading (Form 4)
Latest: 2026-09-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Ishay Davidi | Director | Grant (A) | +86,500 opt | — | EDGAR | |
| 2026-09-29 | Uri Botzer | Director | Grant (A) | +60,000 opt | — | EDGAR | |
| 2026-09-29 | Lilach Asher-Topilsky | Director | Grant (A) | +86,500 opt | — | EDGAR | |
| 2026-09-25 | Amir London | Chief Executive Officer | Grant (A) | +800,000 opt | — | EDGAR | |
| 2026-09-24 | Shavit Beladev | VP Plasma Operations | Grant (A) | +75,000 opt | — | EDGAR | |
| 2026-09-24 | Lilach Payorski | Director | Grant (A) | +60,000 opt | — | EDGAR | |
| 2026-09-24 | Boris Gorelik | VP, BD and Strategic Programs | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-09-24 | Karnit Goldwasser | Director | Grant (A) | +86,500 opt | — | EDGAR | |
| 2026-09-24 | Liron Reshef | VP Human Resources | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-09-23 | Yael Brenner | VP Quality | Grant (A) | +60,000 opt | — | EDGAR | |
| 2026-09-23 | Nir Livneh | VP, General Counsel | Grant (A) | +89,485 opt | — | EDGAR | |
| 2026-09-23 | Eran Nir | VP, Operations | Grant (A) | +112,500 opt | — | EDGAR | |
| 2026-09-23 | David Tsur | Director | Grant (A) | +37,500 opt | — | EDGAR | |
| 2026-09-23 | Leon Recanati | Director | Grant (A) | +86,500 opt | — | EDGAR | |
| 2026-09-23 | Assaf Itshayek | Director | Grant (A) | +46,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
KMDA Insider Holdings
2 insiders · @ $8.08
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David Tsur | Director | 407,929 | $3.30M | -$1.65M | 7 | 2026-09-23 |
| 2 | Yael Brenner | VP Quality | 6,266 | $50.6K | $0 | 5 | 2026-09-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
7 ETFs hold KMDA
7 shown · $985.04K total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | DISV Dimensional International Small Cap Value ETF | Nport | 0.01% | $265,167 | — | 2026-10-31 |
| 2 | DFIS Dimensional International Small Cap ETF | Nport | 0.01% | $261,531 | — | 2026-10-31 |
| 3 | DFIC Dimensional International Core Equity 2 ETF | Nport | 0.00% | $233,584 | — | 2026-10-31 |
| 4 | DFAX Dimensional World ex. U.S. Core Equity 2 ETF | Nport | 0.00% | $110,148 | — | 2026-10-31 |
| 5 | ISCF iShares International Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.01% | $62,691 | $660.2M | 2026-10-08 |
| 6 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.03% | $34,016 | — | 2026-10-08 |
| 7 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.01% | $17,905 | — | 2026-10-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | — | — | — | — |
| Q4 '24 | 2024-12-31 | — | — | — | — |
| Q4 '23 | 2023-12-31 | — | — | — | — |
| Q4 '22 | 2022-12-31 | — | — | — | — |
| Q4 '21 | 2021-12-31 | — | — | — | — |
| Q4 '20 | 2020-12-31 | — | — | — | — |
| Q4 '19 | 2019-12-31 | — | — | — | — |
| Q4 '18 | 2018-12-31 | — | — | — | — |
| Q4 '17 | 2017-12-31 | — | — | — | — |
| Q4 '16 | 2016-12-31 | — | — | — | — |
| Q2 '16 | 2016-06-30 | $19.07M | $-1.58M | $-0.04 | $-6.50M |
| Q1 '16 | 2016-03-31 | $14.80M | $-2.30M | $-0.06 | $7.54M |
Q4 2025 • period ending 2025-12-31 • filed 2026-03-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.56
P/S
5.11
EV/EBITDA
—
EV/Sales
4.97
ROE
-4.3%
ROA
-2.9%
Div Yield
0.00%
FCF Yield
-1.44%
Debt/Equity
0.02
Current Ratio
—
Market Cap
$304.23M
as of 2026-10-09
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
209.48K
SI % of Float
0.67%
Days to Cover
1.82
Short Vol Ratio
64.6%
Free Float
31.40M
Float %
54.6%
Short interest 2026-09-30 • Short volume 2026-10-09 • Float 2025-08-05